Neuropharmacology and biological addiction research

Massa piller som rasar ner i olika färger

Description

We study brain diseases

Welcome to the research group Neuropharmacology and Biological Addiction Research at Uppsala University. We are a diverse and competent group focused on understanding the underlying causes of brain diseases and improving treatment methods. By utilizing a broad methodological platform, our research spans from cell-level studies to various in vivo analyses.

Spruta och tabletter

Our research areas include:

  • Addiction: We investigate how addictive substances affect the brain and work on pharmacological strategies to reduce drug-related harm
  • Cognition: We study the brain's role in memory and learning, as well as how cognitive disorders can arise from various diseases
  • Schizophrenia: We aim to understand the underlying mechanisms of this mental illness and develop innovative treatment strategies to achieve effective symptom relief
  • Drug Development: We develop and test new drugs for the treatment of brain diseases. Our work includes advanced cellular and in vivo models before clinical trials begin.

Our goal is to increase understanding of brain diseases and contribute to the development of new, effective pharmacological treatment methods.

Svensson A-L, Bucht N, Hallberg M, Nyberg F. (2008) Reversal of opiate-induced apoptosis by human recombinant growth hormone in mice foetus primary hippocampal neuronal cell-cultures. Proc Natl Acad Sci USA. 105: 7304-7308.

Andersson H, Demaegdt H, Vauquelin G, Lindeberg G, Karlén A, Hallberg M. (2008) Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem. 16: 6924-6935.

Nyberg F, Hallberg M. (2013) Growth hormone and cognitive function. Nature Rev Endocrinology. 9: 357-365.

Hallberg M. (2015) Neuropeptides; metabolism to bioactive fragments and the pharmacology of their receptors. Med Res Rev. 35: 464-519.

Diwakarla S, Nylander E, Grönbladh A, Vanga SR, Khan YS, Gutiérrez-de-Terán H, Ng L, Sävmarker J, Lundbäck T, Jenmalm-Jensen A, Andersson H, Engen K, Rosenström U, Larhed M, Åqvist J, Chai SY, Hallberg M. (2016) Binding to and inhibition of insulin-regulated aminopeptidase (IRAP) by macrocyclic disulfides enhance spine density. Molecular Pharmacol. 89: 413-424.

Diwakarla S, Nylander E, Grönbladh A, Vanga S, Khan Y, Gutiérrez-de-Terán H, Savmarker J, Ng L, Pham V, Lundbäck T, Jenmalm-Jensen A, Svensson R, Artursson P, Zelleroth S, Engen K, Rosenström U, Larhed M, Aqvist J, Chai S Y, Hallberg M. (2016) Aryl sulfonamide inhibitors of insulin-regulated aminopeptidase enhance spine density in primary hippocampal neuron cultures. ACS Chem Neurosci. 7: 1383-1392.

Grönbladh A, Nylander E, Hallberg M. (2016) The neurobiology and addiction potential of anabolic androgenic steroids and effects of growth hormone. Brain Res Bull. 126:127-137.

Nylander E, Grönbladh A, Zelleroth S, Diwakarla S, Nyberg F, Hallberg M. (2016) Growth hormone is protective against acute methadone-induced toxicity by modulating the NMDA receptor complex.

Neuroscience. 339: 538-547.

Hallberg M, Sumners C, Steckelings UM, Hallberg A. (2018) Small-molecule AT2 receptor agonists. Med Res Rev. 38:602-624.

Hallberg M, Sandström A. (2018) From the anti-nociceptive substance P metabolite substance P (1-7) to small peptidemimetics. Curr Protein Pept Sci, doi: 10.2174/1389203719666180508122019.

Last modified:

FOLLOW UPPSALA UNIVERSITY ON

facebook
instagram
twitter
youtube
linkedin